A B S T R A C T S
a significant correlation. Significant correlations for ECOG
versus TD and PFS (p=0.0047 and p<0.0001, respectively) and
for MNA versus PFS (p=0.0007) were observed in multivariate
analysis. Subgroup analysis excluding ECOG
2 patients no
longer showed significant correlations for ECOG; only MNA
and G8 (cut-off 12) were significantly associated with TD
(p=0.0481 and p=0.0165, respectively) and with PFS (p=0.0012
and p=0.0017, respectively), while G8 was correlated with
severe treatment toxicity (p=0.018).
In this real-life study in older mCRC patients,
ECOG is a strong predictive marker for TD, PFS and severe
toxicity, mainly driven by a subpopulation of patients with
2. MNA and G8 are predictive markers for TD and PFS
(and toxicity for G8) in the large group of patients with ECOG
Disclosure of interest:
Bevacizumab, ECOG, Elderly, fTRST, geriatric
CANCER SURVIVORSHIP AND AGING – IS IT SO DIFFERENT
FOR ELDERLY AND YOUNG?
*, S. Ouakinin
, S. Eusébio
, L. Ribeiro
, O. Nunes
Hemato-oncology, Hospital CUF infante santo,
Psychology /Psychiatry, Fac Medicine Univ Lisboa,
Hospital CUF descobertas, Lisboa, Portugal
Over the last decades the huge raise of cancer
survivors reflects significant improvement on diagnosis
and treatment of several cancers, as well as the best care of
multiple other diseases. The aging of population contributes
to significant numbers of older patients (on 2030 the number
of people who are older than 65 is expected to double as
compared to 2000). Cancer incidence globally raises with
age, and older patients have special and potentially unmet
needs, so it is important to understand if the comorbidities
are different in elderly and young patients
To compare the incidence and evaluate the
differences of comorbidities on a population of cancer
survivors (more than 10 years after diagnosis), stratifying
patients by age. Data on Quality of Life and distress will be
included on a subset of patients.
Using a retrospective design, in a sample of
198 patients with more than 10 years of cancer survival, we
analysedmedical andpsychiatric comorbidities.Data obtained
from medical records included social and demographic data,
the characterization of tumor type and treatment approach,
the presence of second malignancies and comorbidities such
as diabetes, cardiovascular diseases, arterial hypertension,
lung, renal, hematologic, osteo-articular/ osteoporosis,
neurologic and psychiatric diseases, as well as obesity, pre
and pos-diagnosis and treatment of the malignancy. In a sub
sample of patients, distress levels and Quality of Life were
evaluated. Statistical analysis was performed using Statistical
Package for Social Sciences- SPSS V23.
In the whole sample age is less or equal to 50 years
in 21 subjects, between 51 and 69 years in 95 patients, and
70 years or more in 82 patients; 63,6% of them are females.
The most frequent diagnosis in patients aged 70 or more are
colorectal cancer (48,8%), breast cancer (23,2%), lymphoma
(6,1%) and lung cancer (4,9%). Using a non-parametric test
(Kruskal Wallis) to compare the distribution of comorbidities
in the 3 groups, we found significant differences between
groups for arterial hypertension (p<0.001) and for psychiatric
diseases (p<0.03). All comorbidities increased with age except
for psychiatric diseases, which decreases with age, and for
obesity, more frequent in patients between 51 and 69 years.
Even though the retrospective nature of this
study, it shows few significant differences in medical profiles
in younger and older patients. We highlight the need to
consider particular health aspects in older populations, being
aware of their expected and increasing needs in support and
 Mao J, Armstrong K, Bowman M et al. Symptom
burden among cancer survivors: Impact of age and
comorbidityJABFM Sept-Oct 2007;40:5.434-43.
 Earle CC, Ganz PA. Cancer survivorship care: don’t let the
perfect be enemy of the good. J Clin Oncol. 2012;30:3764-68.
 Ligibel J. Lifestyle factors in cancer survivorship. J Clin
 Siegel R, DeSantis C,Virgo k, et al. Cancer treatment and sur-
vivorship statistics, 2012. CA Cancer J Clin 2012;62:220-41.
 Moslehi J. The cardiovascular perils of cancer survivorship.
N Engl J Med 2013;368:1055-56.
 Brennan ME, Gormally JF, Butow P, et al. Survivorship care
plans in cancer: a systematic review of care plan outcomes.
Br J Cancer 2014; 111:1899-1908.
 National Comprehensive Cancer Network. NCCN Clinical
Practice Guidelines in Oncology: Survivorship (version I.2015)
Disclosure of interest:
Cancer survivorship elderly comorbidities distress
EVALUATION OF THE IMPACT OF COMPREHENSIVE
GERIATRIC ASSESSMENT (CGA) IN OLDER PATIENTS WITH
, R. Boulahssass
*, S. Gonfrier
, D. Saja
, J. M. Turpin
, F. Leborgne
, E. Clais
, E. Francois
UCOG, Centre Antoine Lacassagne, Nice, France
In the future, life expectancy and incidence
of cancer will increase, and also incidence of kidney cancer
will increase in patients over 75 years old. The treatment of
kidney cancer issurgery.We
observe in this population several
comorbidities which increase the risk of surgical morbidity
and could lead to only best supportive care.
The aim of this work is to determine the impact
of CGA in treatment decisions and also in guided geriatric